Ifinatamab Deruxtecan Continues to Demonstrate Promising …
WEBSep 7, 2024 · Ifinatamab deruxtecan is a specifically engineered potential first-in-class B7-H3 directed antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed by Daiichi Sankyo and Merck (NYSE: MRK), known as MSD outside of the United States and Canada.
Ifinatamab Deruxtecan Continues to Demonstrate Durable …
WEBSep 10, 2023 · Ifinatamab deruxtecan is a specifically engineered potential first-in-class B7-H3 directed antibody drug conjugate (ADC) designed using Daiichi Sankyo’s (TSE: 4568) proprietary DXd ADC technology.
IASLC: Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung …
WEBSep 9, 2024 · The antibody-drug conjugate ifinatamab deruxtecan (I-DXd) showed clinically meaningful responses in pretreated patients with extensive-stage small cell lung cancer (SCLC) in an interim analysis of the phase II IDeate-Lung01 study.
IDeate-Lung02: A phase 3, randomized, open-label study of ifinatamab …
WEBMay 29, 2024 · I-DXd is a B7-H3-directed antibody–drug conjugate comprising an anti-B7-H3 mAb linked to a topoisomerase I inhibitor payload (DXd) via a stable cleavable linker, designed to enhance selective tumor cell death and reduce systemic exposure.
Abstract 4891: Ifinatamab deruxtecan (I-DXd), a novel B7-H3 …
WEBApr 4, 2023 · Ifinatamab deruxtecan (I-DXd; DS-7300) is a novel ADC which consists of an anti-B7-H3 antibody linked with a DNA topoisomerase I inhibiting anti-tumor agent, DXd. I-DXd has demonstrated potent anti-tumor activity in B7-H3-positive preclinical cancer models and showed early signs of promising clinical efficacy in …
IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated …
WEBAug 1, 2024 · Ifinatamab deruxtecan is a specifically engineered potential first-in-class B7-H3 directed DXd antibody-drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Merck. Small cell lung cancer is the second most common type of lung cancer, accounting for about 15% of cases.
690P Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with …
WEBI-DXd is a novel B7-H3–directed antibody–drug conjugate that leverages the clinically validated deruxtecan (DXd) technology with a plasma-stable linker and potent topoisomerase I inhibitor payload.
WEBAug 1, 2024 · Ifinatamab deruxtecan (I-DXd) is an investigational, potential first-in-class B7-H3 directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC Technology, ifinatamab deruxtecan is comprised of a humanized anti-B7-H3 IgG1 monoclonal antibody attached to a number of topoisomerase I inhibitor
Antibody-Drug Conjugate Ifinatamab Deruxtecan Shows Robust …
WEBJan 4, 2024 · Ifinatamab deruxtecan (I-DXd) is a novel B7-H3–directed antibody-drug conjugate that leverages the clinically validated deruxtecan technology. The compound has a plasma-stable linker and potent topoisomerase I inhibitor payload that can enhance selective tumor cell death and reduce systemic exposure of the payload, Dr. …
WEBIfinatamab deruxtecan (I-DXd) was designed with 7 key attributes. B7-H3 (CD276) is expressed in many solid tumors but is absent or expressed at relatively low levels in normal tissue. High B7-H3 expression is associated with a poor prognosis1–3.
Skip to content